Skip to main content
. 2019 Jan 2;133(11):1205–1216. doi: 10.1182/blood-2018-09-873083

Table 1.

Main clinicobiological features of the patients included in the study

Feature Entire cohort (n = 5290) Non-CK (0-2 abs; n = 4496) CK ≥3 abs (n = 794) Low-CK/intermediate-CK (3-4 abs; n = 523) High-CK (≥5 abs; n = 271) P, non-CK vs CK P, low-CK/intermediate-CK vs high-CK
Male 3302/5290, 62% 2790/4496, 62% 522/794, 66% 351/523, 67% 171/271, 63% .047 .56
Median age (diagnosis) 64.6 y 64.3 y 64.7 y 64.2 y 66.1 y .58 .02
MBL 383/4454, 9% 353/3813, 9% 30/641, 5% 27/412, 7% 3/229, 1% .0001 .004
Binet A 3030/4454, 68% 2643/3813, 69% 387/641, 60% 263/412, 64% 124/229, 54% <.0001 .017
Binet B/C 1041/4454, 23% 817/3813, 22% 224/641, 35% 122/412, 29% 102/229, 45% <.0001 .0002
U-CLL 1514/3453, 44% 1187/2939, 40% 327/514, 64% 201/351, 57% 126/163, 77% <.0001 <.0001
TP53abs 657/4968, 13% 337/4204, 8% 320/764, 42% 151/501, 30% 169/263, 64% <.0001 <.0001
del(11q) 487/4500, 11% 353/3714, 9% 165/622, 26% 119/413, 29% 46/209, 22% <.0001 .07
Trisomy 12 685/4500, 15% 557/3714, 15% 150/622, 24% 117/413, 28% 33/209, 16% <.0001 .0005
idel(13q) 1734/4500, 38% 1621/3714, 44% 113/622, 18% 86/413, 21% 27/209, 13% <.0001 <.0001

The statistically significant level was defined as .008 following the Bonferroni correction for multiple testing. abs, aberrations; CK, ≥3 abs; low-CK, 3 abs; intermediate-CK, 4 abs; high-CK, ≥5 abs; MBL, monoclonal B-cell lymphocytosis; TP53abs, deletion of chromosoe 17p and/or TP53 mutation; del(11q), deletion of chromosome 11q; idel(13q), isolated deletion of chromosome 13q.